Migraine patchmaker NuPathe chooses buyer Teva over Endo; Alnylam enters PhI with hemophilia RNAi drug;

> NuPathe, the maker of the Zecuity transdermal patch for migraine treatment, decided not to accept Endo Health Solutions' ($ENDP) offer of about $105 million and opted instead for Teva Pharmaceutical Industries' ($TEVA) offer of about $114 milliion. More

> Alnylam ($ALNY) entered the clinic with its RNAi candidate ALN-AT3. The Phase I trial will focus on the treatment of hemophilia and rare bleeding disorders. Release

> New Jersey-based Alitair Pharmaceuticals won a U.S. patent for its ion exchange resin drug delivery technology. Release